CTX310 Lipid Disorder: Phase 1 Trial Shows Prom...

By HEOR Staff Writer

November 10, 2025

CTX310 Breakthrough in Lipid Disorder Treatment CTX310 is a significant advancement as the first-in-human Phase 1 trial of this
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss...
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Effici...
Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Center...
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for Ig...
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC
Promising PSMA-Targeted Therapy Delays Prostate Cancer Progression
Johnson & Johnson Advances Solid Tumor Research at ESMO 2025 with Promis...
Tukysa Breast Cancer Therapy Boosts Progression-Free Survival in Advanced Cases
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...